Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

TD Cowen 45th Annual Health Care Conference on March 4 in Boston Leerink Partners Global Biopharma Conference on March 12 in ...

On or about September 15, 2023, Neumora conducted the IPO and raised more than $250 million from the investing public. The lawsuit alleges that, unbeknownst to investors, Neumora's KOASTAL-1 study, ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...